RecruitingAdvanced Solid Tumor
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
Sponsor: BioNTech SE
Where it's recruiting
Kentucky
Louisville
Michigan
Grand Rapids
North Carolina
Huntersville
Rhode Island
East Providence
South Carolina
Charleston
Texas
Dallas · San Antonio
Source: ClinicalTrials.gov · NCT06750185 · last updated 2026-02-11